etacrynic acid
Approved
Jan 10, 1967
Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition. Ethacrynic acid is indicated for the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure. — NCATS
Clinical trial activity
3 trials · 3 clinical orgs · 18 marketing orgs
Earliest trial started Oct 1, 2012 (NCT01628731)
Timeline
1960s
- Jan 10, 1967
Earliest FDA Approval
- Jan 10, 1967
Bausch Health Companies — NDA Secondary Org
- Jan 10, 1967
Bausch Health Companies — Marketing Organization
2010s
- Jan 1, 2012
Earliest Phase 3 Sponsor(trial)
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
- Jul 29, 2015
Bristol-Myers Squibb — Marketing Organization
- Jun 30, 2016
Edenbridge Pharms — Marketing Organization
- Aug 23, 2016
Mylan — Marketing Organization
- Feb 23, 2017
West-Ward Pharmaceutical — Marketing Organization
- Feb 23, 2017
Hikma — Marketing Organization
- Jul 21, 2017
Par Pharmaceuticals — Marketing Organization
- Nov 17, 2017
Zydus Discovery DMCC — Marketing Organization
- May 8, 2018
Amneal Pharmaceuticals — Marketing Organization
- Jul 24, 2018
Alvogen — Marketing Organization
- Jul 12, 2019
Agnitio — Marketing Organization
- Aug 27, 2019
Sciegen Pharmaceticals — Marketing Organization
- Sep 6, 2019
Lupin — Marketing Organization
2020s
- Feb 19, 2020
Upsher-Smith Laboratories — Marketing Organization
- Jun 9, 2020
Vpi Pharms Inc — Marketing Organization
- Oct 19, 2020
Chartwell Pharmaceuticals — Marketing Organization
- Oct 30, 2020
Strides Pharma Science — Marketing Organization
Indications
Approved for
Mechanism of action
SLC12A1 inhibitor
Approval history
- approvedJan 10, 1967
Chemistry & pharmacology
SMILES
C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl- Mol. weight
- 303.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL456 ↗
- WikipediaEtacrynic acid ↗
- NCATSM5DP350VZV ↗
- ChEMBLCHEMBL1200487 ↗
Also known as
- (2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
- (2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
- acide étacrynique
- acide étacrynique
- ácido etacrínico
- ácido etacrínico
- acidum etacrynicum
- acidum etacrynicum
- edecrin
- edecrin
- edecrin
- etacrinic acid
- etacrinic acid
- etacrynic acid
- etacrynic acid
- etacrynic acid
- etacrynic acid
- etacrynic acid
- etakrinic acid
- etakrinic acid
- ethacryinic acid
- ethacryinic acid
- ethacrynate
- ethacrynate
- ethacrynate
- ethacrynate
- ethacrynate sodium
- ethacrynate sodium
- ethacrynate sodium
- ethacrynate sodium
- ethacrynic acid
- ethacrynic acid
- ethacrynic acid
- ethacrynic acid
- ethacrynic acid
- ethacrynic acid
- ethacrynic acid
- hydromedin
- hydromedin
- methylenebutyrylphenoxyacetic acid
- methylenebutyrylphenoxyacetic acid
- mk-595
- mk-595
- reomax
- reomax
- sodium ethacrynate
- sodium ethacrynate
- sodium ethacrynate
- sodium ethacrynate
- sodium ethacrynate
- sodium ethacrynate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02852564 | Phase 1 | Aug 1, 2016 | University of Kansas |
| NCT02051946 | Phase 1/Phase 2 (Phase 2) | May 1, 2014 | Duke University |
| NCT01628731 | Phase 3 | Oct 1, 2012 | Bambino Gesù Hospital and Research Institute |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bambino Gesù Hospital and Research Institute | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Kansas | Academic/Hospital | 1 | 1 | 1 | 2016 |
Marketing (21)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Agnitio | For profit | MKTG | Jul 12, 2019 |
| Alvogen | For profit | MKTG | Jul 24, 2018 |
| Amneal Pharmaceuticals | For profit | MKTG | May 8, 2018 |
| Bausch Health Companies | For profit | NDA2 | Jan 10, 1967 |
| Bausch Health Companies | For profit | MKTG | Jan 10, 1967 |
| Bristol-Myers Squibb | For profit | MKTG | Jul 29, 2015 |
| Chartwell Pharmaceuticals | For profit | MKTG | Oct 19, 2020 |
| Edenbridge Pharms | For profit | MKTG | Jun 30, 2016 |
| Hikma | For profit | MKTG | Feb 23, 2017 |
| Hikma | For profit | SYN | Feb 23, 2017 |
| Lupin | For profit | MKTG | Sep 6, 2019 |
| Merck | For profit | NDA | — |
| Mylan | For profit | MKTG | Aug 23, 2016 |
| Par Pharmaceuticals | For profit | MKTG | Jul 21, 2017 |
| Par Pharmaceuticals | For profit | SYN | Jul 29, 2015 |
| Sciegen Pharmaceticals | For profit | MKTG | Aug 27, 2019 |
| Strides Pharma Science | For profit | MKTG | Oct 30, 2020 |
| Upsher-Smith Laboratories | For profit | MKTG | Feb 19, 2020 |
| Vpi Pharms Inc | For profit | MKTG | Jun 9, 2020 |
| West-Ward Pharmaceutical | For profit | MKTG | Feb 23, 2017 |
| Zydus Discovery DMCC | For profit | MKTG | Nov 17, 2017 |